US 11,730,724 B2
Methods of treatment
Sundar Srinivasan, Corona Del Mar, CA (US); and Christina Chow, Seattle, WA (US)
Assigned to BOW RIVER LLC, Corona Del Mar, CA (US)
Filed by Bow River LLC, Corona Del Mar, CA (US)
Filed on Oct. 28, 2020, as Appl. No. 17/82,902.
Application 17/082,902 is a continuation of application No. 16/408,931, filed on May 10, 2019, granted, now 10,857,144.
Application 16/408,931 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Prior Publication US 2021/0128543 A1, May 6, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4468 (2006.01); A61K 31/454 (2006.01); A61K 31/519 (2006.01); A61K 31/498 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/407 (2006.01); A61P 35/04 (2006.01); A61K 9/00 (2006.01); A61K 31/5383 (2006.01); A61P 25/18 (2006.01); A61K 31/4995 (2006.01); A61P 25/16 (2006.01); A61K 31/4745 (2006.01); A61K 31/397 (2006.01); A61K 31/5395 (2006.01); A61P 35/02 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/00 (2006.01); A61K 9/10 (2006.01)
CPC A61K 31/4468 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2004 (2013.01); A61K 9/4841 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4995 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01)] 15 Claims
 
1. A method of treating a patient in need thereof with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole,
comprising the steps of:
(a) stopping posaconazole treatment;
(b) delaying administering, for at least 9 days after stopping posaconazole treatment, a dose of the CYP3A4 substrate drug that the patient would have received based on the patient's age and condition if the patient had not been treated with posaconazole; and then
(c) administering the dose of the CYP3A4 substrate drug;
wherein the CYP3A4 substrate drug is selected from the group consisting of cariprazine, crizotinib, sunitinib, tolvaptan, acalabrutinib, ticagrelor, dabrafenib, vemurafenib, fluticasone propionate/salmeterol, and cabozantinib.